Dr. Erik P. Castle spoke at the 23rd annual Perspectives in Urology Point • Counterpoint meeting on Saturday, November 15, 2014 on “Treatment Options for the Small Renal Mass.”
Keywords: renal cell carcinoma, nephron sparing, clinical studies
How to cite: Castle, Erik P. “Treatment Options for the Small Renal Mass” Grand Rounds in Urology. November 15, 2014. Accessed Nov 2024. https://dev.grandroundsinurology.com/renal-cancer-erik-p-castle-small-renal-masses/.
References
Bijol V, Mendez GP, Hurwitz S, et al. Evaluation of the nonneoplastic pathology in tumor nephrectomy specimens: predicting the risk of progressive renal failure. Am J Surg Pathol. 2006 May;30(5):575-84.
http://www.ncbi.nlm.nih.gov/pubmed/16699311
Campbell SC, Novick AC, Belldegrun A, et al. Guideline for management of the clinical T1 renal mass. J Urol. 2009 Oct;182(4):1271-9.
http://www.ncbi.nlm.nih.gov/pubmed/19683266
Huang WC, Levey AS, Serio AM, et al.
Chronic kidney disease after nephrectomy in patients with renal cortical tumours: a retrospective cohort study. Lancet Oncol. 2006 Sep;7(9):735-40.
http://www.ncbi.nlm.nih.gov/pubmed/16945768
Lau WK, Blute ML, Weaver AL, et al. Matched comparison of radical nephrectomy vs nephron-sparing surgery in patients with unilateral renal cell carcinoma and a normal contralateral kidney. Mayo Clin Proc. 2000 Dec;75(12):1236-42.
http://www.ncbi.nlm.nih.gov/pubmed/11126830
McKiernan J, Simmons R, Katz J, et al. Natural history of chronic renal insufficiency after partial and radical nephrectomy. Urology. 2002 Jun;59(6):816-20.
http://www.ncbi.nlm.nih.gov/pubmed/12031359
Thompson RH, Boorjian SA, Lohse CM, et al. Radical nephrectomy for pT1a renal masses may be associated with decreased overall survival compared with partial nephrectomy. J Urol. 2008 Feb;179(2):468-71; discussion 472-3.
http://www.ncbi.nlm.nih.gov/pubmed/18076931
ABOUT THE AUTHOR
Dr. Erik P. Castle is a Professor of Urology at the Mayo Clinic College of Medicine. His surgical expertise includes minimally invasive urologic oncology, including robot-assisted radical cystectomy, prostatectomy, retroperitoneal lymph node dissection, and partial nephrectomy. He has demonstrated many of these procedures internationally, as he pioneered robot cystectomy as well as robot RPLND. He directs the International Laparoscopic Nephrectomy Program in Mexico on behalf of the American Urologic Association (AUA), and also serves on several committees and guideline panels within the American Urologic Association. He is on the Early Detection of Prostate Cancer Panel for the National Comprehensive Cancer Network (NCCN) as well.
Dr. Castle’s research interests include prostate cancer, bladder cancer, and kidney cancer. He is the Director of the Desert Mountain Care Prostate Cancer Research Fund and is the principal investigator of his lab housed at the Mayo Clinic Collaborative Research Building. His basic science research is focused on novel secondary hormonal therapies of prostate cancer and apoptotic pathways related to manipulations of the androgen and estrogen receptors. He also directs the prospectively collected genitourinary biorepository at Mayo Clinic Arizona, which houses over 40,000 specimens.
